Compare · BJDX vs MDLN
BJDX vs MDLN
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BJDX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 8205.2x BJDX ($5.4M).
- Over the past year, BJDX is down 34.3% and MDLN is down 17.1% - MDLN leads by 17.2 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 11 for BJDX).
- MDLN has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- Medline Inc.
- Price
- $5.22+0.00%
- $33.80+0.58%
- Market cap
- $5.4M
- $44.40B
- 1M return
- +179.14%
- -19.55%
- 1Y return
- -34.26%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 11
- 20
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
- Director Wurth Douglas Clark bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)
- President and CEO Dey Indranil bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 56,818% to 12,522 units (SEC Form 4)
- Director Chase Donald R bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 50,000% to 12,525 units (SEC Form 4)
- Director Zeidman Fred S bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)